期刊文献+

树突状细胞联合化疗治疗晚期胃肠道肿瘤前后IFN-γ、IL-10、IL-12的实验研究 被引量:6

Experimental study of IFN-γ,IL-10,and IL-12 in patients with advanced gastrointestinal cancer before and after treatment with dendritic cell combined chemotherapy
原文传递
导出
摘要 目的探讨致敏的树突状细胞联合化疗治疗胃肠道恶性肿瘤的IFN-γ、IL-10和IL-12的动态变化,建立评价树突状细胞疗效的特异性免疫指标及毒副作用。方法 40例晚期的胃癌和结直肠癌患者随机分为树突状细胞联合化疗组和单纯化疗组,治疗组化疗前分离患者外周血单核细胞,体外培养成致敏的树突状细胞,培养期间给予患者1周期的5-氟尿嘧啶(5-FU)、亚叶酸钙(CF)和奥沙利铂(L-OHP)方案的化疗,化疗后回输树突状细胞,对照组给予患者同一方案的化疗,治疗前后检测血清中的IFN-γ、IL-10、和IL-12,并观察卡氏评分和毒副作用。结果观察组生物化疗后IFN-γ、IL-12和卡氏评分升高,IL-10下降,对照组化疗后IL-10水平上升,IFN-γ、IL-12和卡氏评分下降,均有统计学意义;观察组行树突状细胞回输时,未发现Ⅲ度以上的毒副作用。结论 IFN-γ、IL-10、IL-12是树突状细胞治疗肿瘤的特异性免疫效果的指标,树突状细胞能够减轻化疗的毒副反应,提高免疫功能,改善患者的生活质量。 To establish the specific immunological indexes of sensitized dendritic cell,we observed the change of IFN-γ,IL10,and IL-12 in the peripheral blood of gastrointestinal cancer patients before and after dendritic cell combined with chemotherapy,and investigated the side effect of the combined chemotherapy in gastrointestinal cancer.Firstly,forty patients with advanced gastric cancer or colorectal cancer were randomly divided into chemotherapy group (control group) and dendritic cell combined with chemotherapy group (observing group).Then sensitized matured DCs were collected from peripheral blood monocytes of the patients in observing group before chemotherapy,which were loaded tumor lysate and cultivated in vitro.In the course of cultivation,the patients in observing group received Oxaliplatin (L-OHP) plus 5-FU/CF.After chemotherapy,the sensitized matured DC were administered to the patients in observing group,while patients in control group received the treatment of the same regimen except the DC administration.The concentrations of IFN-γ,IL-10,IL-12 in blood serum were detected before and after treatment,at the same time the toxicity and KPS of these treatment were observed.In observing group,the concentrations of IFN-γ and IL-12 in blood serum and the KPS were significantly increased,but the concentration of IL-10 was decreased after treatment;on the other hand,in control group,the concentrations of IFN-γ and IL-12 in blood serum and the KPS were decreased,but the concentration of IL-10 was increased after chemotherapy.In observing group,when sensitized matured DCs were administered,no serious side effect was observed.The results showed that IFN-γ,IL-10,IL-12 are the specific immunological indexes of sensitized dendritic cell therapy,furthermore,dendritic cell can decrease side effect of chemotherapy,enhance immune function,and improve patients'quality of life.
出处 《免疫学杂志》 CAS CSCD 北大核心 2010年第8期702-705,709,共5页 Immunological Journal
关键词 树突状细胞 IFN-Γ IL-10 IL-12 化疗 胃肠道肿瘤 Dendritic cell IFN-γ IL-10 IL-12 Chemotherapy Gastrointestinal cancer
  • 相关文献

参考文献10

二级参考文献33

  • 1吴春艳,张俐,郑世民.电磁场对动物免疫系统的影响及其机理[J].免疫学杂志,2004,20(z1):118-120. 被引量:6
  • 2罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量:18
  • 3徐道华,夏永鹏,邱宗荫,吴玉章,贾正才,邹丽云,周伟.γ干扰素增强CTL对宫颈癌细胞杀伤作用及其机制研究[J].免疫学杂志,2005,21(3):205-207. 被引量:1
  • 4侯小明,赵达,马守成.FOLFOX4方案治疗晚期胃癌临床研究[J].临床肿瘤学杂志,2006,11(12):915-917. 被引量:14
  • 5Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-selfcytotoxic T lymphocytes by recombinant adeno-associated virusbased gene loading of dendritic cells [ J ]. Cancer Gene Ther,2005,12(3) :304 - 312.
  • 6Midgley R, Kerr DJ, Mirza N, et al. A phase Ⅱ dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [J]. Proc Am Soc Clin Oncol,2002,21:23b.
  • 7Chang JWC,Hsieh JJ,Chen J S, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma [ J ]. ProcAm Soc Clin Oncol,2002,21:3b.
  • 8Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells[J ]. Eur J Immunol, 2002,32(1) :30 - 38.
  • 9Slichenmyer WJ,Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases[J]. Semin Oncol, 2001,28 (Suppl 16) :S67 - S79.
  • 10Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as firstline and maintenance therapy for patients with indolent nonhodgkin's lymphoma[J]. J Clin Oncol,2002,20(20):4261 -4267.

共引文献44

同被引文献70

引证文献6

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部